<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04709094</url>
  </required_header>
  <id_info>
    <org_study_id>ACH471-017</org_study_id>
    <secondary_id>CA27858</secondary_id>
    <nct_id>NCT04709094</nct_id>
  </id_info>
  <brief_title>A Drug Interaction Study of Danicopan</brief_title>
  <official_title>A Three-Part Phase 1 Study to Evaluate the Potential Drug Interaction Between ACH-0144471 and Warfarin, Bupropion, and Ethinyl Estradiol and Norethindrone (Oral Contraceptive) in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexion Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Achillion, a wholly owned subsidiary of Alexion</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Celerion</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Alexion Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This was a 3-part study (Part 1, Part 2, Part 3) with each part being an open-label, fixed&#xD;
      sequence, 2-period study in healthy adult participants.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study was conducted to assess the 2-way interaction between danicopan and warfarin (Part&#xD;
      1), bupropion (Part 2), and ethinyl estradiol/norethindrone (EE/NET) as an oral contraceptive&#xD;
      (Part 3).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 28, 2019</start_date>
  <completion_date type="Actual">April 17, 2020</completion_date>
  <primary_completion_date type="Actual">October 14, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Part 1, Part 2, and Part 3 could be conducted concurrently or separately.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1: Area Under The Concentration Versus Time Curve From Time 0 Extrapolated To Infinity (AUC0-inf) Of Single-dose Warfarin Under Multiple Doses Of Danicopan</measure>
    <time_frame>Up to 168 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Maximum Observed Concentration (Cmax) Of Single-dose Warfarin Under Multiple Doses Of Danicopan</measure>
    <time_frame>Up to 168 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Time To Maximum Observed Concentration (Tmax) Of Single-dose Warfarin Under Multiple Doses Of Danicopan</measure>
    <time_frame>Up to 168 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: AUC0-inf Of Single-dose Bupropion Under Multiple Doses Of Danicopan</measure>
    <time_frame>Up to 96 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Cmax Of Single-dose Bupropion Under Multiple Doses Of Danicopan</measure>
    <time_frame>Up to 96 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Tmax Of Single-dose Bupropion Under Multiple Doses Of Danicopan</measure>
    <time_frame>Up to 96 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 3: AUC0-inf Of Single-dose EE/NET Under Multiple Doses Of Danicopan</measure>
    <time_frame>Up to 96 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 3: Cmax Of Single-dose EE/NET Under Multiple Doses Of Danicopan</measure>
    <time_frame>Up to 96 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 3: Tmax Of Single-dose EE/NET Under Multiple Doses Of Danicopan</measure>
    <time_frame>Up to 96 hours postdose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 1: International Normalized Ratio (INR) Of Single-dose Warfarin Under Multiple Doses Of Danicopan</measure>
    <time_frame>Up to 168 hours postdose</time_frame>
    <description>Blood samples will be collected for prothrombin time/INR determination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Number Of Participants With Treatment-emergent Adverse Events (TEAEs) After Multiple Doses Of Danicopan Coadministered With A Single Dose Of Warfarin</measure>
    <time_frame>Day 1 (postdose) through follow-up (14 [+/- 2] days after last study drug administration)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Number Of Participants With TEAEs After Multiple Doses Of Danicopan Coadministered With A Single Dose Of Bupropion</measure>
    <time_frame>Day 1 (postdose) through follow-up (14 [+/- 2] days after last study drug administration)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 3: Number Of Participants With TEAEs After Multiple Doses Of Danicopan Coadministered With A Single Dose Of EE/NET</measure>
    <time_frame>Day 1 (postdose) through follow-up (14 [+/- 2] days after last study drug administration)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Part 1: Danicopan and Warfarin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Participants received a single dose of warfarin.&#xD;
Period 2: Participants received danicopan three times daily, in addition to coadministration with a single dose of warfarin.&#xD;
Scheduled pharmacokinetics (PK) and pharmacodynamics samples were collected, with a washout period of at least 14 days between the dose of warfarin in Period 1 and the first dose of danicopan in Period 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Danicopan and Bupropion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Participants received a single dose of bupropion.&#xD;
Period 2: Participants received danicopan three times daily, in addition to coadministration with a single dose of bupropion.&#xD;
Scheduled PK samples were collected, with a washout period of at least 7 days between the dose of bupropion in Period 1 and the first dose of danicopan in Period 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3: Danicopan and EE/NET</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Participants received a single dose of EE/NET.&#xD;
Period 2: Participants received danicopan three times daily, in addition to coadministration with a single dose of EE/NET.&#xD;
Scheduled PK samples were collected, with a washout period of at least 7 days between the dose of EE/NET in Period 1 and the first dose of danicopan in Period 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Danicopan</intervention_name>
    <description>Danicopan was dosed as 2 x 100 milligram (mg) tablets.</description>
    <arm_group_label>Part 1: Danicopan and Warfarin</arm_group_label>
    <arm_group_label>Part 2: Danicopan and Bupropion</arm_group_label>
    <arm_group_label>Part 3: Danicopan and EE/NET</arm_group_label>
    <other_name>ACH-0144471</other_name>
    <other_name>ALXN2040</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin</intervention_name>
    <description>Warfarin was dosed as 2 x 10 mg and 1 x 5 mg warfarin sodium tablets (Coumadin or generic equivalent).</description>
    <arm_group_label>Part 1: Danicopan and Warfarin</arm_group_label>
    <other_name>Coumadin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupropion</intervention_name>
    <description>Bupropion was dosed as Wellbutrin (or generic equivalent) as 1 x 100 mg tablet.</description>
    <arm_group_label>Part 2: Danicopan and Bupropion</arm_group_label>
    <other_name>Bupropion HCl</other_name>
    <other_name>Wellbutrin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ethinyl Estradiol/Norethindrone</intervention_name>
    <description>EE/NET (0.035 mg/1 mg) was dosed as Ortho-Novum-1/35 (or generic equivalent) fixed-dose combination tablets.</description>
    <arm_group_label>Part 3: Danicopan and EE/NET</arm_group_label>
    <other_name>Ortho-Novum</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Parts 1 and 2: adult males or females between 18 and 55 years of age, inclusive, at&#xD;
             screening. Part 3: adult females between 18 and 65 years of age, inclusive, at&#xD;
             screening.&#xD;
&#xD;
          2. Body mass index in the range of 18.0 to 32.0 kilograms (kg)/meter squared, inclusive,&#xD;
             with a minimum body weight of 50.0 kg at screening.&#xD;
&#xD;
          3. No clinically significant history or presence of electrocardiogram abnormalities at&#xD;
             screening.&#xD;
&#xD;
          4. Non-sterile male participants must agree to abstinence or use a highly effective&#xD;
             method of contraception.&#xD;
&#xD;
          5. Female participants must be of non-childbearing potential and need not employ a method&#xD;
             of contraception.&#xD;
&#xD;
          6. Part 1 only: Participant has a negative fecal occult blood test at screening.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Clinically significant laboratory abnormalities.&#xD;
&#xD;
          2. History of any medical or psychiatric condition or disease that might limit the&#xD;
             participant's ability to complete or participate in this clinical study, confound the&#xD;
             results of the study, or pose an additional risk to the participant by their&#xD;
             participation in the study.&#xD;
&#xD;
          3. History or presence of drug or alcohol abuse within previous 2 years, current&#xD;
             tobacco/nicotine user, or positive for alcohol and/or drug screen at screening or Day&#xD;
             -1 of Period 1.&#xD;
&#xD;
          4. History or presence of clinically significant seizures, head injury, or head trauma.&#xD;
&#xD;
          5. History of procedures that could alter absorption or excretion of orally administered&#xD;
             drugs.&#xD;
&#xD;
          6. History of meningococcal infection, or a first-degree relative with a history of&#xD;
             meningococcal infection.&#xD;
&#xD;
          7. A history of significant multiple and/or severe allergies or has had an anaphylactic&#xD;
             reaction or significant intolerability to prescription or non-prescription drugs.&#xD;
&#xD;
          8. Body temperature ≥ 38.0°Celsius at screening or prior to first dosing in Period 1 or&#xD;
             history of febrile illness, or other evidence of infection, within 14 days prior to&#xD;
             first dosing.&#xD;
&#xD;
          9. Donation of whole blood from 3 months prior to first dosing, or of plasma from 30 days&#xD;
             before first dosing, or receipt of blood products within 6 months prior to first&#xD;
             dosing.&#xD;
&#xD;
         10. Participation in any other investigational study drug trial in which receipt of an&#xD;
             investigational study drug occurred within 5 half-lives (if known) or 30 days before&#xD;
             first dosing, whichever is longer.&#xD;
&#xD;
             Part 1 Only:&#xD;
&#xD;
         11. History or presence of any of the following, with clinical significance:&#xD;
&#xD;
               -  bleeding disorder(s), including relevant familial history;&#xD;
&#xD;
               -  anemia (for example, history of temporary anemia during pregnancy is acceptable);&#xD;
&#xD;
               -  thromboembolic disease;&#xD;
&#xD;
               -  bleeding in the gastrointestinal tract or central nervous system.&#xD;
&#xD;
         12. Has active severe gingivitis.&#xD;
&#xD;
         13. Clinically significant illness, clinically significant surgery, including tooth&#xD;
             extraction, trauma, or head injury, within 28 days before Day 1 of Period 1.&#xD;
&#xD;
         14. Participant is employed or actively involved in any circumstance that would place them&#xD;
             at increased risk of hemorrhage during the study (for example, contact sports,&#xD;
             strenuous or unaccustomed weight lifting, running, bicycling).&#xD;
&#xD;
         15. Participant has taken large daily doses of vitamin K (&gt; 25 micrograms/daily) and/or&#xD;
             has a diet rich in vitamin K 14 days prior to the first dosing.&#xD;
&#xD;
             Part 2 Only:&#xD;
&#xD;
         16. Any significant finding on the Columbia-suicide severity rating scale.&#xD;
&#xD;
         17. History or presence of any of the following, with clinical significance:&#xD;
&#xD;
               -  bulimia or anorexia nervosa;&#xD;
&#xD;
               -  hypertension;&#xD;
&#xD;
               -  angle-closure glaucoma;&#xD;
&#xD;
               -  seizure disorder;&#xD;
&#xD;
               -  prior seizure to previous bupropion administration;&#xD;
&#xD;
               -  head trauma.&#xD;
&#xD;
             Part 3 Only:&#xD;
&#xD;
         18. History or presence of:&#xD;
&#xD;
               -  migraines or severe headaches;&#xD;
&#xD;
               -  thrombotic disorders (thrombophlebitis, deep vein thrombosis);&#xD;
&#xD;
               -  cerebrovascular accident;&#xD;
&#xD;
               -  hypertension;&#xD;
&#xD;
               -  transient ischemic attacks;&#xD;
&#xD;
               -  undiagnosed vaginal bleeding;&#xD;
&#xD;
               -  liver tumors or liver disease;&#xD;
&#xD;
               -  jaundice with previous use of oral contraceptives or past pregnancy;&#xD;
&#xD;
               -  diabetes (including gestational diabetes);&#xD;
&#xD;
               -  carcinoma of the endometrium, breast or other known or suspected estrogen&#xD;
                  dependent neoplasia;&#xD;
&#xD;
               -  family history of first degree relative with breast, ovarian, cervical, or&#xD;
                  endometrial/uterine cancer;&#xD;
&#xD;
               -  history of abnormal pap smear (high-grade squamous intraepithelial lesion or&#xD;
                  greater result) including positive human papilloma virus test and/or cervical&#xD;
                  cancer, or history of cervical procedures including loop electrosurgical excision&#xD;
                  procedure or conization;&#xD;
&#xD;
               -  any condition that would contraindicate the use of oral contraceptives.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinical Study Site</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 12, 2021</study_first_submitted>
  <study_first_submitted_qc>January 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 14, 2021</study_first_posted>
  <last_update_submitted>January 12, 2021</last_update_submitted>
  <last_update_submitted_qc>January 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Factor D Inhibitor</keyword>
  <keyword>Complement</keyword>
  <keyword>Danicopan</keyword>
  <keyword>Oral Contraceptive</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Pharmacodynamics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupropion</mesh_term>
    <mesh_term>Warfarin</mesh_term>
    <mesh_term>Ethinyl Estradiol</mesh_term>
    <mesh_term>Norethindrone</mesh_term>
    <mesh_term>Norethindrone Acetate</mesh_term>
    <mesh_term>Norinyl</mesh_term>
    <mesh_term>Norethindrone acetate, ethinyl estradiol, ferrous fumarate drug combination</mesh_term>
    <mesh_term>Estradiol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

